A clinical study about contrast nephropathy: risk factors and the role of beta blockers.

objectiveThere is still a group of patient that have unpredictable risk for the development of contrast nephropathy (CN). There is also an effort to find more effficient strategies to prevent CN. Carvedilol, metoprolol and nebivolol seem to have theoretical potentials for the prevention of CN. In this study, we aimed to investigate their effects on the prevention of CN. We also aimed to define the risk factors associated with the development of CN in our study group.

methodsIn this prospective, cross-sectional study, the patients were divided into four groups according to whether they were taking 25 mg/day carvedilol (n:56), 5 mg/day nebivolol (n:60), 50 mg/day metoprolol (n:68) or none (n:63). We made analysis to determine the agents' efficiency on the prevention of CN. We also performed multiple logistic regression analysis including all groups to define the risk factors associated with CN.

resultsThe incidents of CN were the lowest in the carvedilol group (4%) while the worst performance occurred in those taking metoprolol (10%). The difference between the groups in terms of the development of CN did not reach statistical significance (p>0.05). Multiple logistic regression analysis showed age (p=0.003), higher triglyceride levels (p=0.011) and family history of coronary artery disease (p=0.038) to be the predictors of CN.

conclusionIn this study, we didn't find any relation between the development of CN and carvedilol, metoprolol or nebivolol usage. We found age, higher levels of triglyceride and family history of coronary artery disease to be risk factors for predicting CN.